Büyüme Hormonu Eksikliğinin Tanı Kriterleri Yeniden Değerlendirilmelidir

Öz

Giriş: Bu çalışmada, hastanemizde büyüme hormonu BH eksikliği tanısıyla izlenençocuklarda tedaviye yanıtı belirleyen etkenlerin belirlenmesi amaçlanmıştır. Gereç ve Yöntem: İzole idyopatik BH eksikliği nedeniyle takip edilen ve BH tedavisikullanan toplam 149 hastanın verileri retrospektif olarak incelendi. Bulgular: Tanı aşamasında bakılan ortalama maksimum BH yanıtı klonidin stimülasyontesti için 4,58 ng/ml, glukagon stimülasyon testi için ise 6,01 ng/ml bulundu. OrtalamaBH dozu 0,215 0,18-0,25 mg/kg/hafta olarak belirlendi. BH tedavisi ile boy SDS anlamlıolarak arttı p< 0,05 . Klonidin ve glukagon uyarısına maksimum BH yanıtı ile boyuzaması arasındaki ilişki negatif yönde anlamlı bulundu p< 0,05 . Uyarı testlerineverilen maksimum yanıta göre hastalar 7 ng/ml olarak ayrıldığında,tedaviye en yüksek yanıtın hem klonidin ve hem de glukagon testlerinde 0,05 . Sonuç: Tedaviye erken başlanan, uyarı testlerinde daha düşük BH yanıtı veren ve dahayüksek doz BH verilen hastaların tedaviden daha çok yarar gördüğü saptandı. Bunedenle, BH eksikliği tanı kriterlerinin gözden geçirilmesi gerektiği, uyarı testlerindekabul edilen 10 ng/ml sınırının aşırı tanı konmasına neden olabileceği görüldü. Daha genişserilerde yapılacak araştırmalarda nihai boyların da değerlendirilmesi ile tanıkriterlerinin yeniden belirlenmesi gerektiği vurgulandı

Anahtar Kelimeler

• Büyüme hormonu eksikliği,büyüme hormonu tedavisi

Diagnostic Criteria of Growth Hormone Deficiency Needs to be Reevaluated

Öz

In tro duc ti on: In this study, we aimed to investigate the factors that determine responseto growth hormone GH treatment in children with isolated idiopathic GH deficiencytreated in our university hospital. Materials and Methods: The data of 149 patients followed in our university hospital betweenJanuary 1995 and December 2005 were evaluated in patient charts retrospectively. Results: The maximum GH response to clonidine and glucagon stimulation tests was4.58 and 6.01 ng/ml respectively. The mean GH dose was 0.215 0.18-0.25 mg/kg/week.Height SDS significantly increased after the first and second years of GH treatment p< 0.05 . There was a negative correlation between the maximum response tostimulation tests and the response to GH treatment p< 0.05 . When the patients weregrouped according to the maximum response to stimuli as 7 ng/ml,the best response to therapy was observed in the group with the least response 0.05 .Conclusions: Patients who were started treatment at an early age, whose response to GH stimulation tests were lower, andwho were given higher doses benefited more from GH treatment. Therefore, we suggest that the diagnostic criteria for GHdeficiency must be reevaluated and the random cut-off of

Anahtar Kelimeler

• Growth hormone deficiency,growth hormone treatment

Kaynakça

1. 1. Allen DB, Johanson AJ, Blizzard RM: Growth hormone treatment; In Lifshitz F (ed): Pediatric Endocrinology. 3rd edition. New York: Marcel Dekker; 1996. 61-81.
2. 2. Guyda HJ. Four decades of growth hormone therapy for short children: what have we achieved? J Clin Endocrinol Metab 1999;84:4307-16.
3. 3. Bundak R, Hindmarsh PC, Brook CG. Long-term auxologic effects of human growth hormone. J Pediatr 1988;112:875-9.
4. 4. Coste J, Letrait M, Carel JC, Tresca JP, Chatelain P, Rochiccioli P, et al. Long term results of growth hormone treatment in France in children of short stature: population, register based study. BMJ 1997;315:708-13.
5. 5. Ranke MB, Price DA, Albertsson-Wikland K, Maes M, Lindberg A. Factors determining pubertal growth and final height in growth hormone treatment of idiopathic growth hormone deficiency. Analysis of 195 Patients of the Kabi Pharmacia International Growth Study. Horm Res 1997;48:62-71.
6. 6. Cole TJ, Hindmarsh PC, Dunger DB. Growth hormone (GH) provocation tests and the response to GH treatment in GH deficiency. Arch Dis Child 2004;89:1024-7.
7. 7. Ranke MB, Lindberg A, Chatelain P, Wilton P, Cutfield W, Albertsson-Wikland K, et al. Derivation and validation of a mathematical model for predicting the response to exogenous recombinant human growth hormone (GH) in prepubertal children with idiopathic GH deficiency. KIGS International Board. Kabi Pharmacia International Growth Study. J Clin Endocrinol Metab 1999;84:1174-83.
8. 8. Nathan BM, Allen DB. Growth Hormone Treatment. In: Lifshitz F (eds). Pediatric Endocrinology. 5rd edition. New York: Informa; 2007:113-43.

9. 9. Greulich WW, Pyle SI, (eds) Radiographic atlas of skeletal development of the hand and wrist. Second edition, Stanford University Press; 1959.
10. 10. Neyzi O, Günöz H, Furman A, Bundak R, Gökçay G, Darendeliler F, et al. Türk çocuklarında vücut ağırlığı, boy uzunluğu, baş çevresi ve vücut kitle indeksi referans değerleri. Çocuk Sağlığı ve Hastalıkları Dergisi 2008;51:1-14.
11. 11. Lifshitz F, Botero D. Growth and growth disorders In: Lifshitz F. (eds). Pediatric Endocrinology. 4rd edition. Newyork: MarcelDekker; 2004:1-18.
12. 12. Chatelain P. Trends in the diagnosis and treatment of short stature as revealed by KIGS In: Ranke MB and Wilton P (eds): Growth Hormone Therapy in KIGS 10 Years Experience. Heidelberg: Leipzig: Barth J&J;1999. 11-20.
13. 13. Reiter EO, Rosenfeld RG. Normal and aberrant growth In: Wilson ID, Foster DW, Kronenberg HM, Larsen PR (eds): Williams Text Book of Endocrinology. 9th edition. Philadelphia: WB Saninders Company; 1998. 1427-507.
14. 14. Dündar B, Böber E, Büyükgebiz A. Results of growth hormone treatment applied during twelve years period in Dokuz Eylül University, school of medicine, Department of Pediatric Endocrinology. Dokuz Eylül Üniversitesi Tıp Fakültesi Dergisi 2004;18: 55-65.
15. 15. Tanner JM, Whitehouse RH, Marubini E, Resele LF. The adolescent growth spurt of boys and girls of the Harpenden growth study. Ann Hum Biol 1976;3:109-26.